Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

被引:0
|
作者
Shaffer, Brian C. [1 ]
Gooptu, Mahasweta [2 ]
Defor, Todd E. [3 ]
Maiers, Martin [3 ]
Bolanos-Meade, Javier [4 ]
Abboud, Ramzi [5 ]
Briggs, Adrienne D. [6 ]
Khimani, Farhad [7 ]
Modi, Dipenkumar [8 ]
Newcomb, Richard [9 ]
Shpall, Elizabeth J. [10 ]
Bupp, Caitrin [3 ]
Spellman, Stephen R. [3 ]
Stefanski, Heather E. [3 ]
Shaw, Bronwen E. [11 ]
Auletta, Jeffery J. [3 ,12 ]
Devine, Steven M. [3 ]
Jimenez, Antonio M. Jimenez [13 ]
Al Malki, Monzr M. [14 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY USA
[2] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA USA
[3] NMDP, Ctr Int Blood & Marrow Transplant Res, CIBMTR, Minneapolis, MN 55401 USA
[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] HonorHlth, Canc Transplant Inst, Scottsdale, AZ USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immuno, Tampa, FL USA
[8] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA
[11] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, CIBMTR, Milwaukee, WI USA
[12] Nationwide Childrens Hosp, Hematol Oncol BMT & Infect Dis, Columbus, OH USA
[13] Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[14] City Hope Natl Med Ctr, Duarte, CA USA
关键词
HEMATOPOIETIC-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; PHASE-II TRIAL; HEMATOLOGIC MALIGNANCIES; HLA; BLOOD; INDEX; PREVENTION; ABATACEPT; GVHD;
D O I
10.1200/JCO.24.00184
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)-based prophylaxis. Methods Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. Results Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syndromes (29.2%). Median patient age was 60.7 years (range, 18.0-82.7) and median follow-up was 36.6 (range, 3.0-77.8) months. When compared with MUD HCT with PTCy, MMUD HCT with PTCy had similar OS (hazard ratio [HR], 0.96 [95% CI, 0.823 to 1.11]; P = .60) and GRFS (HR, 0.90 [0.79 to 1.02]; P = .1). When compared with MUD HCT with CNI, OS was improved after MUD HCT with PTCy (HR, 0.88 [0.80 to 0.96]; P = .004) and GRFS was improved with PTCy after either MUD (HR, 0.61 [0.57 to 0.66]; P < .0001) or MMUD (HR, 0.68 [0.60 to 0.76]; P < .0001) HCT. Benefit from PTCy was independent of patient ancestry. Global registry level analysis demonstrated that inclusion of MMUD increased donor availability regardless of recipient ancestry. Conclusion Use of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation
    Al Malki, Monzr M.
    Bo-Subait, Stephanie
    Logan, Brent
    Olson, Janelle
    Leckrone, Erin
    Wu, Juan
    Stefanski, Heather E.
    Auletta, Jeffery J.
    Spellman, Stephen R.
    Malmberg, Craig
    Shaffer, Brian C.
    Modi, Dipenkumar
    Khimani, Farhad
    Gooptu, Mahasweta
    Hamadani, Mehdi
    Broglie, Larisa
    Shaw, Bronwen E.
    Devine, Steven Michael
    Jimenez, Antonio Martin Jimenez
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Antithymocyte globulin-based Prophylaxis for Graft Versus Host Disease Compared to Post-Transplant Cyclophosphamide-based Prophylaxis in Matched Unrelated Donor Transplantation
    Champ, D.
    Kwon, M.
    Pascual Cascon, M. J.
    Balsalobre, P.
    Vidales Mancha, I.
    Serrano, D.
    Anguita, J.
    Buno, I.
    Gayoso, J.
    Diez-Martin, J. -L.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S178 - S178
  • [3] Antithymocyte Globulin-Based Prophylaxis for Graft Versus Host Disease Compared to Post-Transplant Cyclophosphamide-Based Prophylaxis in Matched Unrelated Donor Transplantation
    Velao, Sara Redondo
    Kwon, Mi
    Champ, Diana
    Cascon, M. J. Pascual
    Balsalobre, Pascual
    Diez, J.
    Mancha, I. Vidales
    Serrano, David
    Fernandez, Noemi
    Anguita, Javier
    Buno, Ismael
    Gayoso, Jorge
    Diez-Martin, Jose Luis
    [J]. BLOOD, 2016, 128 (22)
  • [4] Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in pediatric patients with hematologic malignancies transplanted from haploidentical and matched unrelated donors
    Abrosimov, A.
    Shelikhova, L.
    Shekhovtsova, Z.
    Skvortsova, J.
    Muzalevsky, I.
    Kazachenok, A.
    Ilushina, M.
    Shipitsina, I.
    Shasheleva, D.
    Khismatullina, R.
    Blagov, S.
    Gutovskaya, E.
    Myakova, N.
    Litvinov, D.
    Novichkova, G.
    Maschan, A.
    Maschan, M.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S460 - S460
  • [5] POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES TRANSPLANTED FROM HAPLOIDENTICAL AND MATCHED UNRELATED DONORS
    Abrosimov, A.
    Shelikhova, L.
    Shekhovtsova, Z.
    Balashov, D.
    Skvortsova, Y.
    Kurnikova, E.
    Ilushina, M.
    Shipitsina, I.
    Shasheleva, D.
    Khismatullina, R.
    Gutovskaya, E.
    Blagov, S.
    Myakova, N.
    Litvinov, D.
    Baidildina, D.
    Novichkova, G.
    Maschan, M.
    Maschan, A.
    [J]. HAEMATOLOGICA, 2016, 101 : 636 - 636
  • [6] Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis
    Aljawai, Yosra M.
    Tsai, Hua-Ling
    Varadhan, Ravi
    Jones, Richard J.
    Imus, Philip H.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [7] Comparison between Post-Transplant Cyclophosphamide Use and Conventional Prophylaxis of Graft-Versus-Host Disease: A Retrospective Study
    Prato, Caio Branicio
    Justino, Caio Cesar
    Tavares, Ana Paula
    Leonel, Rayana Bomfim
    Arruda de Moraes, Pedro Henrique
    Fonseca, Ana Marcela
    Azevedo, Roberta Santos
    de Molla, Vinicius Campos
    Arrais-Rodrigues, Celso
    [J]. BLOOD, 2023, 142
  • [8] Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease
    Pingali, Sai Ravi
    Milton, Denai
    Popat, Uday R.
    Hosing, Chitra M.
    Bashir, Qaiser
    Alousi, Amin M.
    Jones, Roy
    Nieto, Yago
    Kebriaei, Partow
    Qazilbash, Muzaffar H.
    Andersson, Borje S.
    Shpall, Elizabeth J.
    Khouri, Issa F.
    Champlin, Richard E.
    Ciurea, Stefan O.
    [J]. BLOOD, 2014, 124 (21)
  • [9] Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis (GvHD) in pediatric patients with acute lymphoid leukemia (ALL) transplanted from haploidentical and matched unrelated donors
    Abrosimov, A.
    Shelikhova, L.
    Shekhovtsova, Z.
    Starichkova, J.
    Balashov, D.
    Kurnikova, E.
    Ilyushina, M.
    Shipitsina, I.
    Shasheleva, D.
    Khismatullina, R.
    Gutovskaya, E.
    Blagov, S.
    Bogoyavlenskaya, A.
    Alyabieva, M.
    Radygina, S.
    Kozlovskaya, S.
    Mitrakov, K.
    Myakova, N.
    Litvinov, D.
    Novichkova, G.
    Maschan, M.
    Maschan, A.
    [J]. BONE MARROW TRANSPLANTATION, 2017, 52 : S374 - S374
  • [10] A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation
    Al Malki, Monzr M.
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Mokhtari, Sally
    Cao, Thai
    Ali, Haris
    Salhotra, Amandeep
    Arslan, Shukaib
    Aldoss, Ibrahim
    Karras, Nicole
    Zain, Jasmine
    Khaled, Samer K.
    Stein, Anthony S.
    Snyder, David S.
    Marcucci, Guido
    Forman, Stephen J.
    Nademanee, Auayporn
    Nakamura, Ryotaro
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S188 - S188